Clinical Trial Search

Primary: PTH (Parathyroid Hormone) Adherence — 0.23; 0.28 probability of having a PTH measured — p=0.04

Primary: Number of Participants With CKD Diagnosis — 417; 389 Participants — p=.21

Primary: Mortality — 0; 0 percentage of mortality

Primary: Change is Leptin to Adiponectin Ratio (LAR) — 2.2; 1.3; 1.3; 1.4 ng/micrograms

Primary: Patient Activation Measure (PAM) -13 Item Questionnaire — 9.1; -1.4 points — p=0.01

Primary: Number of Participants With Treatment-related Adverse Events — 0 Participants

Primary: Fibroblast Growth Factor 23 (FGF-23) — 162.695; 297; 188.975; 143.7675 RU/ml

Primary: Change From Baseline to 12 Weeks in Systolic Ambulatory Blood Pressure in the Chlorthalidone Group Compared to Placebo. — -11.0; -0.5 mm Hg

Primary: Systolic Blood Pressure (SBP) — 135.1; 134.4 mmHg — p=0.57

Primary: Effect of Vitamin D Supplementation on Albuminuria in CKD Patients as Assessed by Urine Albumin/Creatinine Measures. — 1126.68; 1061.39 mg/gram creatinine

Primary: Change in Subjective Units of Distress Scale (SUDS) Score — 2.92; 3.12 score on a scale

Primary: Composite of Dialysis Initiation, Kidney Transplantation, and Serum Creatinine Doubling. Number of Participants Meeting the Criteria Are Reported. — 172; 183 participants

Primary: Composite of Dialysis Initiation, Kidney Transplantation, and Serum Creatinine Doubling. Number of Participants Meeting the Criteria Are Reported. — 178; 177 participants

Primary: Qualitative Survey Assessmentof Perceived Usefulness of the Med-alert Device. — 1 Likert scale

Primary: Phosphocreatine (PCR) Recovery Time After Knee Extension Assessed by 31 Phosphorus Magnetic Resonance Spectroscopy (31P-MRS) — 60.59; 62.66 seconds

Primary: Change in Blood Pressure — -1; -2; -2; -2 mmHg

Primary: Incidence of Death From Any Cause or Myocardial Infarction — 123; 129 Participants

Primary: Change in Peak Aerobic Capacity — 17.1; 16.8; 17.9; 15.9 ml/kg/min

Primary: the Occurrence of Cardiovascular Event and Peritonitis Events — 0; 0; 0; 0 participants — p=>0.05

Primary: Difference in A1c Levels — 8.86; 8.21; 7.95; 8.44 percentage — p=0.00045

Primary: Difference in Mean CKD Register Patient eGFRs Between Groups After 3.5 Years of Study — -2.00; -2.29 mean average eGFR change/mL/min/1.73 m^2

Primary: In Vitro Lipoprotein Functions — 20.8; 26.5 Percentage of cholesterol content

Primary: Peak Oxygen Consumption — 3.07 ml/min/kg

Primary: Percentage Changes in Fibroblast Growth Factor-23 (FGF-23) Levels — -0.35; 0.25; 0.00; -0.02 percentage of change from baseline

Primary: The Discrete Incidence of Any of the Chronic Kidney Disease Patient Safety Indicators (CKD-PSIs) Endorsed by the Consensus Expert Panel — 108.7; 100.6; 38.3; 41.2 events…

Primary: Renal Failure Event Defined as Greater Than or Equal to 40% Decline in Estimated Glomerular Filtration Rate (eGFR) or Occurrence of End Stage Renal Disease (ESRD) — 9.7…

Primary: Change of Systolic Ambulatory Blood Pressure From Baseline to 12 Weeks — -10.5 mmHg — p=0.01

Primary: Change in the Concentration of High Sensitivity C-Reactive Protein (hsCRP) From Baseline to 12 Weeks — -2.6; 0.8 mg/dl — p=0.03

Primary: Sit to Stand to Sit Speed: Time Taken to Sit to Stand to Sit 10 Times — 23.8; 22.9 seconds

Primary: Mean Glucose Concentration Measured by CGM — 151.5 mg/dL